{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T01:53:04Z","timestamp":1790992384861,"version":"4.1.0"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:00Z","timestamp":1790899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:00Z","timestamp":1790899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Chem"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Knowledge of the targets of therapeutic compounds is vital for understanding their action mechanisms and side effects, but such valuable data is seldom available. The multiple complementary techniques needed for comprehensive target characterization must combine data reliability with sufficient analysis throughput. Here, we leveraged the Proteome Integral Solubility Alteration (PISA) assay to characterize the targets of 67 approved and experimental compounds against two main lung cancer subtypes, which is now provided through the website\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/thermotargetminer.serve.scilifelab.se\/app\/thermotargetminer\" ext-link-type=\"uri\">https:\/\/thermotargetminer.serve.scilifelab.se\/app\/thermotargetminer<\/jats:ext-link>\n                    . Novel target candidates (pro-targets) were found for 77% of the tested molecules. Comparison of the protein solubility shifts in lysate vs. living cells highlighted the targets directly interacting with the compounds. We verified that the drug PEITC exerts cytotoxicity through the inhibition of a pro-target PAFAH1B. As PISA is now joining the arsenal of fast and reliable target characterization techniques, the presented database, ThermoTargetMiner, will become a useful resource in lung cancer research.\n                  <\/jats:p>","DOI":"10.1038\/s42004-026-02207-z","type":"journal-article","created":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T11:54:45Z","timestamp":1790942085000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["ThermoTargetMiner as a proteome integral solubility alteration target database for prospective drugs against lung cancer"],"prefix":"10.1038","volume":"9","author":[{"given":"Hezheng","family":"Lyu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3072-4929","authenticated-orcid":false,"given":"Hassan","family":"Gharibi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bohdana","family":"Sokolova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6175-4015","authenticated-orcid":false,"given":"M\u00fccahit","family":"Varli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Voiland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brady","family":"Nilsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaowei","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5610-0797","authenticated-orcid":false,"given":"Massimiliano","family":"Gaetani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2639-6328","authenticated-orcid":false,"given":"Amir Ata","family":"Saei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9839-2089","authenticated-orcid":false,"given":"Roman A.","family":"Zubarev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,2]]},"reference":[{"key":"2207_CR1","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/S0140-6736(21)00312-3","volume":"398","author":"AA Thai","year":"2021","unstructured":"Thai, A. A., Solomon, B. J., Sequist, L. V., Gainor, J. F. & Heist, R. S. Lung cancer. Lancet 398, 535\u2013554 (2021).","journal-title":"Lancet"},{"key":"2207_CR2","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr.2016.06.07","author":"C Zappa","year":"2016","unstructured":"Zappa, C. & Mousa, S. A. Non-small cell lung cancer: Current treatment and future advances. Transl. Lung Cancer Res. https:\/\/doi.org\/10.21037\/tlcr.2016.06.07 (2016).","journal-title":"Transl. Lung Cancer Res."},{"key":"2207_CR3","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/j.mayocp.2019.01.013","volume":"94","author":"N Duma","year":"2019","unstructured":"Duma, N., Santana-Davila, R. & Molina, J. R. Non\u2013small cell lung cancer: epidemiology, screening, diagnosis, and treatment. Mayo Clin. Proc. 94, 1623\u20131640 (2019).","journal-title":"Mayo Clin. Proc."},{"key":"2207_CR4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41572-020-00235-0","volume":"7","author":"CM Rudin","year":"2021","unstructured":"Rudin, C. M., Brambilla, E., Faivre-Finn, C. & Sage, J. Small-cell lung cancer. Nat. Rev. Dis. Prim. 7, 3 (2021).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"2207_CR5","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1038\/nrd.2016.184","volume":"15","author":"RK Harrison","year":"2016","unstructured":"Harrison, R. K. Phase II and phase III failures: 2013-2015. Nat. Rev. Drug Discov. 15, 817\u2013818 (2016).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2207_CR6","doi-asserted-by":"publisher","first-page":"15772","DOI":"10.1021\/acs.analchem.2c03506","volume":"94","author":"P Sabatier","year":"2022","unstructured":"Sabatier, P., Beusch, C. M., Meng, Z. & Zubarev, R. A. System-wide profiling by proteome integral solubility alteration assay of drug residence times for target characterization. Anal. Chem. 94, 15772\u201315780 (2022).","journal-title":"Anal. Chem."},{"key":"2207_CR7","doi-asserted-by":"publisher","first-page":"3049","DOI":"10.1016\/j.apsb.2022.02.002","volume":"12","author":"D Sun","year":"2022","unstructured":"Sun, D., Gao, W., Hu, H. & Zhou, S. Why 90% of clinical drug development fails and how to improve it? Acta Pharm. Sin. B 12, 3049\u20133062 (2022).","journal-title":"Acta Pharm. Sin. B"},{"key":"2207_CR8","doi-asserted-by":"crossref","unstructured":"Lin, A. et al. Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials. Sci. Transl. Med. 11, eaaw8412 (2019).","DOI":"10.1126\/scitranslmed.aaw8412"},{"key":"2207_CR9","doi-asserted-by":"publisher","first-page":"15835","DOI":"10.1073\/pnas.0605224103","volume":"103","author":"M Vedadi","year":"2006","unstructured":"Vedadi, M. et al. Chemical screening methods to identify ligands that promote protein stability, protein crystallization, and structure determination. Proc. Natl. Acad. Sci. USA 103, 15835\u201315840 (2006).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2207_CR10","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1126\/science.1233606","volume":"341","author":"DM Molina","year":"2013","unstructured":"Molina, D. M. et al. Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay. Science 341, 84\u201387 (2013).","journal-title":"Science"},{"key":"2207_CR11","doi-asserted-by":"publisher","DOI":"10.1126\/science.1255784","author":"MM Savitski","year":"2014","unstructured":"Savitski, M. M. et al. Tracking cancer drugs in living cells by thermal profiling of the proteome. Science https:\/\/doi.org\/10.1126\/science.1255784 (2014).","journal-title":"Science"},{"key":"2207_CR12","doi-asserted-by":"publisher","first-page":"4027","DOI":"10.1021\/acs.jproteome.9b00500","volume":"18","author":"M Gaetani","year":"2019","unstructured":"Gaetani, M. et al. Proteome Integral Solubility Alteration: A High-Throughput Proteomics Assay for Target Deconvolution. J. Proteome Res. 18, 4027\u20134037 (2019).","journal-title":"J. Proteome Res."},{"key":"2207_CR13","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1021\/acs.analchem.9b04531","volume":"92","author":"X Zhang","year":"2020","unstructured":"Zhang, X. et al. Solvent-Induced Protein Precipitation for Drug Target Discovery on the Proteomic Scale. Anal. Chem. 92, 1363\u20131371 (2020).","journal-title":"Anal. Chem."},{"key":"2207_CR14","doi-asserted-by":"publisher","first-page":"7066","DOI":"10.1021\/acs.analchem.2c00391","volume":"94","author":"CM Beusch","year":"2022","unstructured":"Beusch, C. M., Sabatier, P. & Zubarev, R. A. Ion-based proteome-integrated solubility alteration assays for systemwide profiling of protein\u2212molecule interactions. Anal. Chem. 94, 7066\u20137074 (2022).","journal-title":"Anal. Chem."},{"key":"2207_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-021-21540-6","volume":"12","author":"AA Saei","year":"2021","unstructured":"Saei, A. A. et al. System-wide identification and prioritization of enzyme substrates by thermal analysis. Nat. Commun. 12, 1\u201313 (2021).","journal-title":"Nat. Commun."},{"key":"2207_CR16","doi-asserted-by":"publisher","first-page":"6768","DOI":"10.3390\/molecules28196768","volume":"28","author":"AA Saei","year":"2023","unstructured":"Saei, A. A. et al. Massive Solubility Changes in Neuronal Proteins upon Simulated Traumatic Brain Injury Reveal the Role of Shockwaves in Irreversible Damage. Molecules 28, 6768 (2023).","journal-title":"Molecules"},{"key":"2207_CR17","doi-asserted-by":"publisher","unstructured":"Saei, A. A. et al. Mapping the GALNT1 substrate landscape with versatile proteomics tools. bioRxiv 2022.08.24.505189 https:\/\/doi.org\/10.1101\/2022.08.24.505189 (2022).","DOI":"10.1101\/2022.08.24.505189"},{"key":"2207_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13582-8","author":"AA Saei","year":"2019","unstructured":"Saei, A. A. et al. ProTargetMiner as a proteome signature library of anticancer molecules for functional discovery. Nat. Commun. https:\/\/doi.org\/10.1038\/s41467-019-13582-8 (2019).","journal-title":"Nat. Commun."},{"key":"2207_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/srep11176","volume":"5","author":"A Chernobrovkin","year":"2015","unstructured":"Chernobrovkin, A., Marin-Vicente, C., Visa, N. & Zubarev, R. A. Functional Identification of Target by Expression Proteomics (FITExP) reveals protein targets and highlights mechanisms of action of small molecule drugs. Sci. Rep. 5, 1\u20139 (2015).","journal-title":"Sci. Rep."},{"key":"2207_CR20","doi-asserted-by":"publisher","first-page":"5527","DOI":"10.1158\/1078-0432.CCR-16-0569","volume":"22","author":"S Zhang","year":"2016","unstructured":"Zhang, S. et al. The potent ALK inhibitor brigatinib (AP26113) overcomes mechanisms of resistance to first- and second-generation ALK inhibitors in preclinical models. Clin. Cancer Res. 22, 5527\u20135538 (2016).","journal-title":"Clin. Cancer Res."},{"key":"2207_CR21","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.lungcan.2019.10.033","volume":"139","author":"DE Gerber","year":"2020","unstructured":"Gerber, D. E. et al. Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer. Lung Cancer 139, 60\u201367 (2020).","journal-title":"Lung Cancer"},{"key":"2207_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/cddiscovery.2015.34","volume":"1","author":"FS Wolenski","year":"2015","unstructured":"Wolenski, F. S. et al. The NAE inhibitor pevonedistat (MLN4924) synergizes with TNF-\u03b1 to activate apoptosis. Cell Death Discov. 1, 1\u20139 (2015).","journal-title":"Cell Death Discov."},{"key":"2207_CR23","doi-asserted-by":"publisher","first-page":"D638","DOI":"10.1093\/nar\/gkac1000","volume":"51","author":"D Szklarczyk","year":"2023","unstructured":"Szklarczyk, D. et al. The STRING database in 2023: protein-protein association networks and functional enrichment analyses for any sequenced genome of interest. Nucleic Acids Res. 51, D638\u2013D646 (2023).","journal-title":"Nucleic Acids Res."},{"key":"2207_CR24","doi-asserted-by":"publisher","first-page":"4973","DOI":"10.1158\/1078-0432.CCR-11-2967","volume":"18","author":"T Shimamura","year":"2012","unstructured":"Shimamura, T. et al. Ganetespib (STA-9090), a Non-Geldanamycin HSP90 Inhibitor, has Potent Antitumor Activity in In Vitro and In Vivo Models of Non-Small Cell Lung Cancer. Clin. Cancer Res. 18, 4973 (2012).","journal-title":"Clin. Cancer Res."},{"key":"2207_CR25","doi-asserted-by":"crossref","unstructured":"Wishart, D. S. et al. DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 36, D901\u2013D906 (2008).","DOI":"10.1093\/nar\/gkm958"},{"key":"2207_CR26","doi-asserted-by":"publisher","first-page":"13481","DOI":"10.1073\/pnas.172501499","volume":"99","author":"PTR Rajagopalan","year":"2002","unstructured":"Rajagopalan, P. T. R. et al. Interaction of dihydrofolate reductase with methotrexate: Ensemble and single-molecule kinetics. Proc. Natl. Acad. Sci. USA 99, 13481 (2002).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2207_CR27","unstructured":"Mendel, D. B. et al. In Vivo Antitumor Activity of SU11248, a Novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic\/pharmacodynamic relationship. http:\/\/aacrjournals.org\/clincancerres\/article-pdf\/9\/1\/327\/2084179\/df0103000327.pdf."},{"key":"2207_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-020-18998-1","volume":"11","author":"E Beauchamp","year":"2020","unstructured":"Beauchamp, E. et al. Targeting N-myristoylation for therapy of B-cell lymphomas. Nat. Commun. 11, 1\u201316 (2020).","journal-title":"Nat. Commun."},{"key":"2207_CR29","doi-asserted-by":"publisher","first-page":"4342","DOI":"10.1111\/bph.13213","volume":"172","author":"L Mooney","year":"2015","unstructured":"Mooney, L., Skinner, M., Coker, S. J. & Currie, S. Effects of acute and chronic sunitinib treatment on cardiac function and calcium\/calmodulin-dependent protein kinase II. Br. J. Pharmacol. 172, 4342 (2015).","journal-title":"Br. J. Pharmacol."},{"key":"2207_CR30","doi-asserted-by":"publisher","first-page":"6818","DOI":"10.1073\/pnas.1814279116","volume":"116","author":"V Modi","year":"2019","unstructured":"Modi, V. & Dunbrack, R. L. Defining a new nomenclature for the structures of active and inactive kinases. Proc. Natl. Acad. Sci. USA 116, 6818\u20136827 (2019).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2207_CR31","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/nbt1358","volume":"26","author":"MW Karaman","year":"2008","unstructured":"Karaman, M. W. et al. A quantitative analysis of kinase inhibitor selectivity. Nat. Biotechnol. 26, 127\u2013132 (2008).","journal-title":"Nat. Biotechnol"},{"key":"2207_CR32","doi-asserted-by":"crossref","unstructured":"Wang, X., Zhang, Y., Han, Z. G. & He, K. Y. Malignancy of cancers and synthetic lethal interactions associated with mutations of cancer driver genes. Medicine 95, e2697 (2016).","DOI":"10.1097\/MD.0000000000002697"},{"key":"2207_CR33","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1038\/nbt.2017","volume":"29","author":"T Anastassiadis","year":"2011","unstructured":"Anastassiadis, T., Deacon, S. W., Devarajan, K., Ma, H. & Peterson, J. R. Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. Nat. Biotechnol. 29, 1039\u20131045 (2011).","journal-title":"Nat. Biotechnol."},{"key":"2207_CR34","first-page":"405","volume":"1846","author":"P Gupta","year":"2014","unstructured":"Gupta, P., Wright, S. E., Kim, S. H. & Srivastava, S. K. Phenethyl Isothiocyanate: a comprehensive review of anti-cancer mechanisms. Biochim. Biophys. Acta 1846, 405 (2014).","journal-title":"Biochim. Biophys. Acta"},{"key":"2207_CR35","doi-asserted-by":"publisher","first-page":"22136","DOI":"10.1074\/jbc.M802330200","volume":"283","author":"L Mi","year":"2008","unstructured":"Mi, L. et al. Covalent Binding to Tubulin by Isothiocyanates: a mechanism of cell growth arrest and apoptosis*. J. Biol. Chem. 283, 22136 (2008).","journal-title":"J. Biol. Chem."},{"key":"2207_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/ncomms4128","volume":"5","author":"R Nilsson","year":"2014","unstructured":"Nilsson, R. et al. Metabolic enzyme expression highlights a key role for MTHFD2 and the mitochondrial folate pathway in cancer. Nat. Commun. 5, 1\u201310 (2014).","journal-title":"Nat. Commun."},{"key":"2207_CR37","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1021\/cb500893q","volume":"10","author":"JW Chang","year":"2015","unstructured":"Chang, J. W. et al. A selective inhibitor of platelet-activating factor acetylhydrolases 1b2 and 1b3 that impairs cancer cell survival. ACS Chem. Biol. 10, 925 (2015).","journal-title":"ACS Chem. Biol."},{"key":"2207_CR38","first-page":"4635","volume":"25","author":"S Edvardson","year":"2016","unstructured":"Edvardson, S. et al. Infantile neurodegenerative disorder associated with mutations in TBCD, an essential gene in the tubulin heterodimer assembly pathway. Hum. Mol. Genet. 25, 4635\u20134648 (2016).","journal-title":"Hum. Mol. Genet."},{"key":"2207_CR39","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1200\/JCO.2004.12.001","volume":"22","author":"S Goodin","year":"2004","unstructured":"Goodin, S., Kane, M. P. & Rubin, E. H. Epothilones: Mechanism of action and biologic activity. J. Clin. Oncol. 22, 2015\u20132025 (2004).","journal-title":"J. Clin. Oncol."},{"key":"2207_CR40","unstructured":"wo2017023866 Method Of Targeting Stat3 and Other Non-Druggable Proteins. https:\/\/patentscope.wipo.int\/search\/en\/detail.jsf?docId=WO2017023866."},{"key":"2207_CR41","doi-asserted-by":"publisher","first-page":"13963","DOI":"10.1016\/S0021-9258(18)71625-6","volume":"264","author":"A Holmgren","year":"1989","unstructured":"Holmgren, A. Thioredoxin and Glutaredoxin systems. J. Biol. Chem. 264, 13963\u201313966 (1989).","journal-title":"J. Biol. Chem."},{"key":"2207_CR42","doi-asserted-by":"publisher","first-page":"7162","DOI":"10.1158\/1078-0432.CCR-19-0302","volume":"25","author":"FEM Froeling","year":"2019","unstructured":"Froeling, F. E. M. et al. Bioactivation of napabucasin triggers reactive oxygen species\u2013mediated cancer cell death. Clin. Cancer Res. 25, 7162 (2019).","journal-title":"Clin. Cancer Res."},{"key":"2207_CR43","doi-asserted-by":"crossref","unstructured":"Jin, H. et al. Systematic transcriptional analysis of human cell lines for gene expression landscape and tumor representation. Nat. Commun. 14, 5417 (2023).","DOI":"10.1038\/s41467-023-41132-w"},{"key":"2207_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-53240-2","volume":"15","author":"TS Batth","year":"2024","unstructured":"Batth, T. S. et al. Streamlined analysis of drug targets by proteome integral solubility alteration indicates organ-specific engagement. Nat. Commun. 15, 8923 (2024).","journal-title":"Nat. Commun."},{"key":"2207_CR45","doi-asserted-by":"crossref","unstructured":"Zhang, X., Lytovchenko, O., Lundstr\u00f6m, S. L., Zubarev, R. A. & Gaetani, M. Proteome Integral Solubility Alteration (PISA) assay in mammalian cells for deep, high-confidence, and high-throughput target deconvolution. Bio. Protoc. 12, e4556 (2022).","DOI":"10.21769\/BioProtoc.4556"},{"key":"2207_CR46","doi-asserted-by":"crossref","unstructured":"Vizca\u00edno, J. A. et al. ProteomeXchange provides globally coordinated proteomics data submission and dissemination. Nat. Biotechnol. 32, 223\u2013226 (2014).","DOI":"10.1038\/nbt.2839"},{"key":"2207_CR47","unstructured":"Klaeger, S. et al. The target landscape of clinical kinase drugs. Science 358, (2017)."},{"key":"2207_CR48","doi-asserted-by":"crossref","unstructured":"Ren, B. J. et al. Alisertib induces cell cycle arrest, apoptosis, autophagy and suppresses EMT in HT29 and Caco-2 cells. Int. J. Mol. Sci. 17, 41 (2016).","DOI":"10.3390\/ijms17010041"},{"key":"2207_CR49","unstructured":"Kl\u00e4ger, S. E. Chemical Proteomics Reveals the Target Landscape of Clinical Kinase Inhibitors."},{"key":"2207_CR50","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1158\/1078-0432.CCR-22-1609","volume":"29","author":"K Peng","year":"2023","unstructured":"Peng, K. et al. Development of combination strategies for Focal Adhesion Kinase inhibition in Diffuse Gastric Cancer. Clin. Cancer Res. 29, 197 (2023).","journal-title":"Clin. Cancer Res."},{"key":"2207_CR51","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1158\/1535-7163.MCT-15-0758","volume":"15","author":"E Ardini","year":"2016","unstructured":"Ardini, E. et al. Entrectinib, a Pan-TRK, ROS1, and ALK inhibitor with activity in multiple molecularly defined cancer indications. Mol. Cancer Ther. 15, 628\u2013639 (2016).","journal-title":"Mol. Cancer Ther."},{"key":"2207_CR52","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1182\/blood-2015-02-629543","volume":"126","author":"TE Witzig","year":"2015","unstructured":"Witzig, T. E. et al. The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma. Blood 126, 328\u2013335 (2015).","journal-title":"Blood"},{"key":"2207_CR53","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/clpt.2009.42","volume":"86","author":"NT Hansen","year":"2009","unstructured":"Hansen, N. T., Brunak, S. & Altman, R. B. Generating genome-scale candidate gene lists for pharmacogenomics. Clin. Pharmacol. Ther. 86, 183 (2009).","journal-title":"Clin. Pharmacol. Ther."},{"key":"2207_CR54","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s40265-020-01464-z","volume":"81","author":"S Dhillon","year":"2021","unstructured":"Dhillon, S. Lonafarnib: first approval. Drugs 81, 283 (2021).","journal-title":"Drugs"},{"key":"2207_CR55","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1124\/mol.106.025866","volume":"70","author":"H Uga","year":"2006","unstructured":"Uga, H. et al. A new mechanism of methotrexate action revealed by target screening with affinity beads. Mol. Pharmacol. 70, 1832\u20131839 (2006).","journal-title":"Mol. Pharmacol."},{"key":"2207_CR56","doi-asserted-by":"publisher","first-page":"573","DOI":"10.3892\/ijmm.2020.4819","volume":"47","author":"X Cao","year":"2021","unstructured":"Cao, X. et al. ROS-mediated hypomethylation of PRDX5 promotes STAT3 binding and activates the Nrf2 signaling pathway in NSCLC. Int. J. Mol. Med. 47, 573 (2021).","journal-title":"Int. J. Mol. Med."},{"key":"2207_CR57","doi-asserted-by":"publisher","first-page":"7162","DOI":"10.1158\/1078-0432.CCR-19-0302","volume":"25","author":"FEM Froeling","year":"2019","unstructured":"Froeling, F. E. M. et al. Bioactivation of napabucasin triggers reactive oxygen species-mediated cancer cell death. Clin. Cancer Res. 25, 7162\u20137174 (2019).","journal-title":"Clin. Cancer Res."},{"key":"2207_CR58","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1517\/13543784.2012.707189","volume":"21","author":"C Marchetti","year":"2012","unstructured":"Marchetti, C. et al. Olaparib, PARP1 inhibitor in ovarian cancer. Expert Opin. Investig. Drugs 21, 1575\u20131584 (2012).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"2207_CR59","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s40265-020-01461-2","volume":"81","author":"CL Braal","year":"2021","unstructured":"Braal, C. L. et al. Inhibiting CDK4\/6 in breast cancer with palbociclib, ribociclib, and abemaciclib: similarities and differences. Drugs 81, 317 (2021).","journal-title":"Drugs"},{"key":"2207_CR60","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1182\/blood-2015-04-640920","volume":"127","author":"NM Czuczman","year":"2016","unstructured":"Czuczman, N. M. et al. Pevonedistat, a NEDD8-activating enzyme inhibitor, is active in mantle cell lymphoma and enhances rituximab activity in vivo. Blood 127, 1128 (2016).","journal-title":"Blood"},{"key":"2207_CR61","doi-asserted-by":"crossref","unstructured":"Upadhyaya, B., Liu, Y. & Dey, M. Phenethyl isothiocyanate exposure promotes oxidative stress and suppresses Sp1 transcription factor in cancer stem cells. Int. J. Mol. Sci. 20, 1027 (2019).","DOI":"10.3390\/ijms20051027"},{"key":"2207_CR62","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1158\/1078-0432.CCR-14-0947","volume":"21","author":"D Sarker","year":"2015","unstructured":"Sarker, D. et al. First-in-human Phase I study of Pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors. Clin. Cancer Res. 21, 77 (2015).","journal-title":"Clin. Cancer Res."},{"key":"2207_CR63","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.1158\/0008-5472.CAN-21-3652","volume":"82","author":"AP Hnatiuk","year":"2022","unstructured":"Hnatiuk, A. P. et al. Reengineering Ponatinib to minimize cardiovascular toxicity. Cancer Res. 82, 2777 (2022).","journal-title":"Cancer Res."},{"key":"2207_CR64","doi-asserted-by":"crossref","unstructured":"Liu, C. et al. Ponatinib inhibits proliferation and induces apoptosis of liver cancer cells, but its efficacy is compromised by its activation on PDK1\/Akt\/mTOR signaling. Molecules 24, 1363 (2019).","DOI":"10.3390\/molecules24071363"},{"key":"2207_CR65","first-page":"2251","volume":"8","author":"I Lugowska","year":"2015","unstructured":"Lugowska, I., Kose\u0142a-Paterczyk, H., Kozak, K. & Rutkowski, P. Trametinib: a MEK inhibitor for management of metastatic melanoma. Onco. Targets Ther. 8, 2251 (2015).","journal-title":"Onco. Targets Ther."},{"key":"2207_CR66","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1038\/sj.bjc.6603463","volume":"95","author":"VM Richon","year":"2006","unstructured":"Richon, V. M. Cancer biology: mechanism of antitumour action of vorinostat (suberoylanilide hydroxamic acid), a novel histone deacetylase inhibitor. Br. J. Cancer 95, S2\u2013S6 (2006).","journal-title":"Br. J. Cancer"}],"container-title":["Communications Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s42004-026-02207-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42004-026-02207-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42004-026-02207-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T01:04:43Z","timestamp":1790989483000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s42004-026-02207-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,2]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2207"],"URL":"https:\/\/doi.org\/10.1038\/s42004-026-02207-z","relation":{},"ISSN":["2399-3669"],"issn-type":[{"value":"2399-3669","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,2]]},"assertion":[{"value":"22 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"312"}}